JP2020504763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504763A5 JP2020504763A5 JP2019544799A JP2019544799A JP2020504763A5 JP 2020504763 A5 JP2020504763 A5 JP 2020504763A5 JP 2019544799 A JP2019544799 A JP 2019544799A JP 2019544799 A JP2019544799 A JP 2019544799A JP 2020504763 A5 JP2020504763 A5 JP 2020504763A5
- Authority
- JP
- Japan
- Prior art keywords
- methylphenidate
- composition
- component
- individual patient
- auc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 85
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical group C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 63
- 229960001344 methylphenidate Drugs 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 46
- 239000002245 particle Substances 0.000 claims description 24
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 21
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 18
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 18
- 239000006186 oral dosage form Substances 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 16
- 239000003456 ion exchange resin Substances 0.000 claims description 14
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 14
- 230000004888 barrier function Effects 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 12
- 239000011324 bead Substances 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 10
- 230000003111 delayed effect Effects 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 238000013265 extended release Methods 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 230000009089 cytolysis Effects 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 claims description 6
- 229960001033 methylphenidate hydrochloride Drugs 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012738 dissolution medium Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 230000000541 pulsatile effect Effects 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 239000013583 drug formulation Substances 0.000 description 10
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415884P | 2016-11-01 | 2016-11-01 | |
| US62/415,884 | 2016-11-01 | ||
| PCT/US2017/059256 WO2018085256A1 (en) | 2016-11-01 | 2017-10-31 | Effective dosing of a child for the treatment of adhd with methylphenidate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504763A JP2020504763A (ja) | 2020-02-13 |
| JP2020504763A5 true JP2020504763A5 (enExample) | 2020-12-10 |
Family
ID=62076554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544799A Pending JP2020504763A (ja) | 2016-11-01 | 2017-10-31 | メチルフェニデートを用いてａｄｈｄを処置するための小児の有効な投薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11166947B2 (enExample) |
| EP (1) | EP3585439A4 (enExample) |
| JP (1) | JP2020504763A (enExample) |
| KR (2) | KR20240033130A (enExample) |
| AU (1) | AU2017353921B2 (enExample) |
| WO (1) | WO2018085256A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4128248B1 (en) * | 2020-03-23 | 2025-12-10 | Genentech, Inc. | Estimating pharmacokinetic parameters using deep learning |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2348871C (en) * | 1998-11-02 | 2009-04-14 | John G. Devane | Multiparticulate modified release composition |
| US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
| WO2013003622A1 (en) * | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
| BR112015003120B1 (pt) * | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
| CA2951072A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
-
2017
- 2017-10-31 JP JP2019544799A patent/JP2020504763A/ja active Pending
- 2017-10-31 AU AU2017353921A patent/AU2017353921B2/en active Active
- 2017-10-31 KR KR1020247006668A patent/KR20240033130A/ko active Pending
- 2017-10-31 US US16/346,850 patent/US11166947B2/en active Active
- 2017-10-31 WO PCT/US2017/059256 patent/WO2018085256A1/en not_active Ceased
- 2017-10-31 EP EP17868418.9A patent/EP3585439A4/en active Pending
- 2017-10-31 KR KR1020197015402A patent/KR20190107655A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2405915T3 (en) | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON | |
| EP3504187B1 (en) | Use of pridopidine for treating functional decline | |
| EP3287124B1 (en) | Oral dosage form of ketamine | |
| JP6233985B2 (ja) | 不眠症の治療用薬剤の遅動型剤形 | |
| CA2746884A1 (en) | A method of treating insomnia | |
| KR20050084589A (ko) | 암페타민 염을 함유한 서방출성 제제 | |
| KR20090015890A (ko) | 저 홍조 니아신 제형 | |
| EA026335B1 (ru) | Снижение флуктуаций опиоидов в крови | |
| Patil et al. | Formulation and in-vitro evaluation of once-daily sustained release matrix tablet of nifedipine using rate retardant polymers | |
| CN105228608B (zh) | 容易调节拉科酰胺或其药学上可允许的盐的溶出模式的药学组合物 | |
| Ermer et al. | Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release | |
| JP2020504763A5 (enExample) | ||
| JP2011506607A5 (enExample) | ||
| AU2017353921B2 (en) | Effective dosing of a child for the treatment of ADHD with methylphenidate | |
| Zheng et al. | Randomized, double-blind, placebo-controlled trial on the efficacy, safety and tolerability of modified-release methylphenidate (MPH-MR) in Chinese children and adolescents with attention-deficit/hyperactivity disorder (ADHD) | |
| CN104220064B (zh) | 一种含辛弗林和托吡酯的联合产品 | |
| CA3251516A1 (en) | Methods of reducing progression of neurodegenerative disease | |
| JP2025519466A (ja) | フロログルシノール製剤および使用方法 | |
| Jigar et al. | Development and evaluation of bilayer gastroretentive tablet containing Metformin HCl SR and pioglitazone HCl IR | |
| TWI634909B (zh) | Long-acting sustained-release medicine composition and preparation method thereof | |
| Linden et al. | Comparison of three metrenperone dosage regimens inhibiting the 5-hydroxytryptamine-induced pulmonary dysfunction in cattle | |
| Barde et al. | Development and In Vitro Evaluation of Extended Release Matrix Tablet of Metoprolol Succinate | |
| Llabres et al. | Gastro-intestinal bioavailability assessment of commercialy prepared sustained-release lithium tablets using a deconvolution technique | |
| WO2019071270A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| HK40009736A (en) | Use of pridopidine for treating functional decline |